%0 Journal Article
%T Effects of Darbepoetin-<i>¦Á</i> on Oxidative  Stress Marker in Patients with Chronic  Renal Failure
%A Norio Nakamura
%A Michiko Shimada
%A Ikuyo Narita
%A Yuko Shimaya
%A Takeshi Fujita
%A Reiichi Murakami
%A Hiroshi Osawa
%A Hideaki Yamabe
%A Ken Okumura
%J Open Journal of Nephrology
%P 8-12
%@ 2164-2869
%D 2014
%I Scientific Research Publishing
%R 10.4236/ojneph.2014.41002
%X <p style=\"text-align:justify;\">
	<span style=\"font-size:10pt;line-height:1.5;font-family:Verdana;\">Objective:</span><span style=\"font-size:10.0pt;line-height:102%;font-family:;\" \"=\"\"> </span><span style=\"font-size:10.0pt;line-height:102%;font-family:;\" \"=\"\"><span style=\"font-family:Verdana;line-height:1.5;\">Long-acting darbepoetin</span><i><span style=\"font-family:Verdana;line-height:1.5;\">-¦Á</span></i><span style=\"font-family:Verdana;line-height:1.5;\"> (DA)
has recently been used to treat renal anemia in patients with chronic renal
failure. It is considered clinically useful because its duration of action is
longer than that of conventional epoetin</span><i><span style=\"font-family:Verdana;line-height:1.5;\">-¦Á</span></i><span style=\"font-family:Verdana;line-height:1.5;\">.
In this study, we investigated changes in the levels of the oxidative stress
marker malondialdehyde-modified low density lipoprotein (MDA-LDL), renal
anemia, and renal function when patients</span></span><span style=\"font-size:10pt;line-height:1.5;font-family:Verdana;\"> were</span><span style=\"font-size:10.0pt;line-height:102%;font-family:;\" \"=\"\"><span style=\"font-family:Verdana;line-height:1.5;\"> treated for chronic renal failure switched from epoetin</span><i><span style=\"font-family:Verdana;line-height:1.5;\">-¦Á</span></i><span style=\"font-family:Verdana;line-height:1.5;\"> to DA.</span></span><span style=\"font-size:10.0pt;line-height:102%;font-family:;\" \"=\"\"> </span><span style=\"font-size:10pt;line-height:1.5;font-family:Verdana;\">Materials and Methods:</span><span style=\"font-size:10.0pt;line-height:102%;font-family:;\" \"=\"\"> </span><span style=\"font-size:10pt;line-height:1.5;font-family:Verdana;\">The subjects included
nine patients with chronic renal failure and renal anemia who were treated with</span><span style=\"font-size:10.0pt;line-height:102%;font-family:;\" \"=\"\"> </span><span style=\"font-size:10.0pt;line-height:102%;font-family:;\" \"=\"\"><span style=\"font-family:Verdana;line-height:1.5;\">epoetin</span><i><span style=\"font-family:Verdana;line-height:1.5;\">-¦Á</span></i><span style=\"font-family:Verdana;line-height:1.5;\"> on an</span></span><span style=\"font-size:10.0pt;line-height:102%;font-family:;\" \"=\"\"> </span><span style=\"font-size:10pt;line-height:1.5;font-family:Verdana;\">outpatient basis at our department. Blood was sampled prior to the
switch and at 3, 6, and 12 months after the switch. We then investigated
changes in MDA-LDL, hemoglobin (Hb), and creatinine (Cr) levels.</span><span
%K Chronic Renal Failure
%K Darbepoetin-&lt
%K i&gt
%K ¦Á&lt
%K /i&gt
%K Epoetin-&lt
%K i&gt
%K ¦Á&lt
%K /i&gt
%K Indoxyl Sulfate
%K MDA-LDL
%K Renal Anemia
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=43548